Donor immune cell treatment after transplant for high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 25 years old or younger when you enroll
- Have high-risk AML, such as certain genetic changes, MRD-positive disease, AML in later remission, or other approved high-risk features
- Be well enough to take part (performance score ≥70%) and have recovered enough after chemotherapy (neutrophils ≥500)
- Have adequate kidney, liver, heart, and lung measurements on recent tests
- Be able to give (or your parent/guardian can give) written consent
- Not have had a prior bone marrow stem cell transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.